Hennion & Walsh Asset Management Inc. Increases Stake in Jazz Pharmaceuticals PLC $JAZZ

Hennion & Walsh Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 25.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 47,535 shares of the specialty pharmaceutical company’s stock after buying an additional 9,657 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.08% of Jazz Pharmaceuticals worth $8,081,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its position in shares of Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth $2,697,000. Kennedy Capital Management LLC purchased a new position in Jazz Pharmaceuticals in the second quarter valued at $1,100,000. Wedge Capital Management L L P NC acquired a new stake in Jazz Pharmaceuticals in the third quarter valued at $27,834,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in Jazz Pharmaceuticals in the third quarter valued at $605,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president owned 56,862 shares in the company, valued at approximately $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,287 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 68,015 shares of company stock worth $13,037,486. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several analyst reports. Piper Sandler upped their price objective on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Friday. Wells Fargo & Company boosted their target price on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Finally, Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $215.38.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $182.69 on Monday. The stock’s 50-day moving average is $175.63 and its two-hundred day moving average is $160.29. The firm has a market cap of $11.25 billion, a price-to-earnings ratio of -30.60, a PEG ratio of 0.33 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $198.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.51 earnings per share. Analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.